<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957047</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-302</org_study_id>
    <nct_id>NCT00957047</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy</brief_title>
  <official_title>Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate
      once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy
      in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who
      complete Part I may enter a 1-year open-label extension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part I was a 22-week parallel-group, randomized, placebo-controlled period (8 weeks baseline,
      2 weeks double-blind titration, and 12 weeks maintenance). After completing the baseline
      period, patients were randomized in a 1:1:1:1 ratio to 1 of the 3 ESL dose levels or to
      placebo.

      Part II was a 1-year open-label extension for patients who had completed Part I. The starting
      dose was 800 mg once daily and could be titrated up or down at 400-mg intervals between 400
      and 1200 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PART I - Seizure Frequency</measure>
    <time_frame>12-week maintenance period</time_frame>
    <description>The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the ITT population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PART II - Nº of Treatment-Emergent Adverse Events (TEAE)</measure>
    <time_frame>1 year</time_frame>
    <description>Safety assessments were based primarily on AEs (Number of patients who experienced at least one AEs), and on whether these were related to the study medication, were serious, led to permanent discontinuation of study participation, or led to death.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Partial Epilepsy</condition>
  <arm_group>
    <arm_group_label>ESL 400 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 1200 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL - Part II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eslicarbazepine acetate</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>ESL 400 mg once daily</arm_group_label>
    <arm_group_label>ESL 800 mg once daily</arm_group_label>
    <arm_group_label>ESL 1200 mg once daily</arm_group_label>
    <other_name>Zebinix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once daily placebo comparator</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESL - Part II</intervention_name>
    <description>Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.</description>
    <arm_group_label>ESL - Part II</arm_group_label>
    <other_name>Eslicarbazepine acetate (ESL), BIA 2-093</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent signed by patient

          -  aged 18 years or more

          -  documented diagnosis of simple or complex partial seizures with or without secondary
             generalisation since at least 12 months prior to screening

          -  at least 4 partial seizures in each 4 week period during the last 8 weeks prior to
             screening, currently treated with 1 or 2 AEDs (any except oxcarbazepine and
             felbamate), in a stable dose regimen during at least 2 months prior to screening
             (patients using vigabatrin should have been on this medication for at least 1 year
             with no deficit in visual field identified)

          -  excepting epilepsy, patient is judged to be in general good health based on medical
             history, physical examination and laboratory tests

          -  post-menopausal or otherwise incapable of becoming pregnant by reason of surgery or
             tubal ligation; in case of woman of childbearing potential, patient must present a
             serum beta-hCG test consistent with a non-gravid state and agree to remain abstinent
             or use reliable contraception (oral contraception should be combined with a barrier
             method

        Exclusion Criteria:

          -  only simple partial seizures with no motor symptomatology (classified as A2-4
             according to the International Classification of Epileptic Seizures) that are not
             video-EEG documented

          -  primarily generalised epilepsy

          -  known rapid progressive neurological disorder; history of status epilepticus or
             cluster seizures (i.e., 3 or more seizures within 30 minutes) within the 3 months
             prior to screening

          -  seizures of psychogenic origin within the last 2 years

          -  history of schizophrenia or suicide attempt

          -  currently on or with exposure to felbamate or oxcarbazepine more within one month of
             screening

          -  using benzodiazepines on more than on an occasional basis (except when used
             chronically as AED)

          -  previous use of ESL or participation in a clinical study with ESL

          -  known hypersensitivity to carbamazepine, oxcarbazepine or chemically related
             substances

          -  history of abuse of alcohol, drugs or medications within the last 2 years

          -  uncontrolled cardiac, renal, hepatic, endocrine, gastrointestinal, metabolic,
             haematological or oncology disorder

          -  second or third-degree atrioventricular blockade not corrected with a pacemaker

          -  relevant clinical laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elinor Ben-Menachem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgren University Hospital, Göteborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Alain Gabbai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rua Pedro de Toledo 655, Vila Clemento, Sao Paulo, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bial - Portela &amp; Cª, S.A.</name>
      <address>
        <city>S. Mamede do Coronado</city>
        <zip>4745-457</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>March 26, 2013</results_first_submitted>
  <results_first_submitted_qc>August 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2013</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory</keyword>
  <keyword>partial</keyword>
  <keyword>epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>STUDY DATES:
PART I - From: 01 Sep 2004 To: 19 Dec 2006; PART II - From: 02 February 2005 To: 29 January 2008 Patients were screened at 46 sites in 13 countries for Part I and Patients from 42 sites in 12 countries continued in part II.;</recruitment_details>
      <pre_assignment_details>Part I was a 22-week parallel-group, randomized, placebo controlled period. After completing the baseline period, patients were randomized in a 1:1:1:1 ratio to 1 of the 3 ESL dose levels or to placebo. For Part I 400 patients were planned; of 503 patients screened, 395 were randomized. 325 patients who completed Part I were enrolled in Part II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo : once daily placebo comparator</description>
        </group>
        <group group_id="P2">
          <title>ESL 400 mg Once Daily</title>
          <description>eslicarbazepine acetate : oral tablets</description>
        </group>
        <group group_id="P3">
          <title>ESL 800 mg Once Daily</title>
          <description>eslicarbazepine acetate : oral tablets</description>
        </group>
        <group group_id="P4">
          <title>ESL 1200 mg Once Daily</title>
          <description>eslicarbazepine acetate : oral tablets</description>
        </group>
        <group group_id="P5">
          <title>ESL - Part II</title>
          <description>All patients in Part II received ESL on an open-label basis, starting at 800 mg once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PART I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized/Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>PART II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="325">325 patients who completed Part I were enrolled in Part II.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Terminated Prematurely</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="102">Terminated Prematurely during 1-year Open-Label Period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ESL 1200 mg Once Daily</title>
          <description>eslicarbazepine acetate : oral tablets</description>
        </group>
        <group group_id="B2">
          <title>ESL 400 mg Once Daily</title>
          <description>eslicarbazepine acetate : oral tablets</description>
        </group>
        <group group_id="B3">
          <title>ESL 800 mg Once Daily</title>
          <description>eslicarbazepine acetate : oral tablets</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>placebo : once daily placebo comparator</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="101"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PART I - Seizure Frequency</title>
        <description>The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the ITT population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.</description>
        <time_frame>12-week maintenance period</time_frame>
        <population>The primary efficacy analysis was an ANCOVA that assessed reduction in seizure frequency per 4 weeks for the ITT population during the 12-week maintenance period</population>
        <group_list>
          <group group_id="O1">
            <title>ESL 1200 mg Once Daily</title>
            <description>eslicarbazepine acetate : oral tablets</description>
          </group>
          <group group_id="O2">
            <title>ESL 400 mg Once Daily</title>
            <description>eslicarbazepine acetate : oral tablets</description>
          </group>
          <group group_id="O3">
            <title>ESL 800 mg Once Daily</title>
            <description>eslicarbazepine acetate : oral tablets</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>placebo : once daily placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>PART I - Seizure Frequency</title>
          <description>The primary efficacy endpoint is the natural log transformation of the seizure frequency per 4 weeks. The primary efficacy analysis was based on the ITT population. Efficacy analyses were performed chiefly using data from the 12-week maintenance period in Part I of the study. The primary efficacy variable is the ln transformation of the seizure frequency per 4 weeks. Seizure frequency was compared between each active treatment group and the placebo group using an ANCOVA that models seizure frequency as a function of baseline seizure frequency and treatment.</description>
          <population>The primary efficacy analysis was an ANCOVA that assessed reduction in seizure frequency per 4 weeks for the ITT population during the 12-week maintenance period</population>
          <units>ln (Seizures) per 4 weeks</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6.0" upper_limit="8.1"/>
                    <measurement group_id="O2" value="8.7" lower_limit="7.7" upper_limit="9.9"/>
                    <measurement group_id="O3" value="7.1" lower_limit="6.2" upper_limit="8.2"/>
                    <measurement group_id="O4" value="9.8" lower_limit="8.7" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PART II - Nº of Treatment-Emergent Adverse Events (TEAE)</title>
        <description>Safety assessments were based primarily on AEs (Number of patients who experienced at least one AEs), and on whether these were related to the study medication, were serious, led to permanent discontinuation of study participation, or led to death.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TEAE</title>
          </group>
          <group group_id="O2">
            <title>TEAE With Onset Within the 1st 4 Weeks</title>
          </group>
          <group group_id="O3">
            <title>TEAE With Onset After 1st 4 Weeks</title>
          </group>
          <group group_id="O4">
            <title>Treatment-related TEAE</title>
          </group>
          <group group_id="O5">
            <title>TEAE Leading to Discontinuation</title>
          </group>
          <group group_id="O6">
            <title>Serious TEAE</title>
          </group>
          <group group_id="O7">
            <title>TEAE Leading to Death</title>
          </group>
        </group_list>
        <measure>
          <title>PART II - Nº of Treatment-Emergent Adverse Events (TEAE)</title>
          <description>Safety assessments were based primarily on AEs (Number of patients who experienced at least one AEs), and on whether these were related to the study medication, were serious, led to permanent discontinuation of study participation, or led to death.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="325"/>
                <count group_id="O6" value="325"/>
                <count group_id="O7" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="240"/>
                    <measurement group_id="O4" value="194"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Tablets; oral route</description>
        </group>
        <group group_id="E2">
          <title>ESL 400 mg</title>
          <description>Tablets; oral route</description>
        </group>
        <group group_id="E3">
          <title>ESL 800 mg</title>
          <description>Tablets; oral route</description>
        </group>
        <group group_id="E4">
          <title>ESL 1200 mg</title>
          <description>Tablets; oral route</description>
        </group>
        <group group_id="E5">
          <title>ESL PART II</title>
          <description>All patients in Part II received ESL</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyskinesia oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hepatic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Follicle centre lymphoma, follicular grade I, II, III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Insulinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="270" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="101"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="101"/>
                <counts group_id="E4" events="43" subjects_affected="43" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="86" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="101"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research Section</name_or_title>
      <organization>Bial - Portela &amp; Cª, S.A.</organization>
      <phone>+ 351 22 986 61 00</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

